In addition, we characterized the predicted KMT2A-CBL protein structure in this patient (Fig. 2) to enhance the understanding of the underlying leukemogenic mechanisms and summarized reported cases of hematological malignancies with KMT2A::CBL fusion to investigate the correlation of gene rearrangements with clinical outcomes. The gene discussed is KMT2A; the disease is hematologic disorder.